The global anti-osteoporosis therapy and fracture healing market is expected to attain a valuation of US$ 14,051.6 million in 2023. The market is projected to reach US$ 22,427.6 million by 2033, anticipated to expand at a CAGR of 4.8% during the forecast period.
The market for osteoporosis treatment is expected to experience growth due to the increasing prevalence of the disease and an increase in the number of affected patients. Key players are primarily focusing on the geriatric population which is helping the market to grow. Additionally, prevalence of bone diseases is also contributing to market growth. Increasing research and development expenditure aimed at generating new drugs is further anticipated to induce growth in the market.
The growing awareness about the diagnosis and treatment of osteoporosis is contributing to the expansion of the market. Additionally, an increase in healthcare facilities such as trauma centers is also driving the growth of the anti-osteoporosis therapy and fracture healing market. Increasing investments in research and development activities for generation of drugs and growing awareness about osteoporosis are also adding to the growth of osteoporosis treatment market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 14,051.6 million |
| Anticipated Forecast Value (2033) | US$ 22,427.6 million |
| Projected Growth Rate (2023 to 2033) | CAGR 4.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The anti-osteoporosis therapy and fracture healing market was worth US$ 11,048.3 million in 2018. It accumulated a market value of US$ 13,442.0 million in 2022. During the historical period from 2018 to 2022, a CAGR of 4.0% was observed.
The global market for anti-osteoporosis therapy and fracture healing is expected to experience continuous growth in the coming years due to the rapid expansion of the healthcare industry and increased healthcare expenditure in emerging economies like China and India. The rising benefits of anti-osteoporosis therapies over other treatments for osteoporosis are also expected to sculpt market growth over the forecast period.
The approval of anti-osteoporosis therapy and fracture healing drugs and injectables by the United States Food and Drug Administration is expected to intensify competition among market players which could more likely aid in market expansion. Many companies are prioritizing the development of advanced products that are easy to use and offer rapid efficacy in the treatment of osteoporosis. For example, Amgen Inc. announced in April 2019 that its EVENITY® had received approval from the United States Food and Drug Administration (FDA) for the treatment of postmenopausal women at high risk of fracture.
Forteo and other companies have demonstrated significant increases in lumbar spine bone mineral density compared to alendronate. Bisphosphonates and estrogen therapy, on the other hand, have chronic side effects such as jaw death, vaginal bleeding, and uterus cancer, highlighting the need for new drugs with fewer or no side effects. Selective estrogen receptor modulators (SERM) drugs like Evista and Duavee were developed to address estrogen's side effects. The anti-osteoporosis therapy and fracture healing market is projected to be worth US$ 22,427.6 million by end of the forecast period while exhibiting a CAGR of 4.8%.
Rising Demand for Non-invasive Therapies to Drive Market Growth
The increasing prevalence of osteoporosis is a key factor driving the global market, as a growing number of patients is expected to drive up demand for drugs and therapy. Additionally, there are no substitutes such as surgery, so the demand for osteoporosis treatment drugs is expected to rise.
The International Osteoporosis Foundation predicted that nearly 50% of global bone fracture incidences will occur in the Asia Pacific region by the end of 2050. The high occurrence and incidence rate of the disease are significant drivers for the market. In addition, the increasing geriatric population is expected to drive market growth in the coming years, although patent expirations of leading brands are likely to considerably slow down the growth rate.
The increasing prevalence of osteopenia and osteogenesis imperfecta (OI) is expected to drive demand for products over the forecast period. The market is also being propelled by the introduction of advanced products and technological advancements.
According to the National Osteoporosis Foundation, calcium deficiency is a major contributor to the increased prevalence of osteoporosis in postmenopausal women. This has become a key driver for anti-osteoporosis therapy and fracture healing demand.
The rising demand for non-invasive therapies is further contributing to the market expansion. Pharmaceutical companies are expected to prioritize improving their production capabilities. The scientific progress made in enhancing product effectiveness and reducing complications has led to increased investment in innovation and the introduction of new products. These efforts are expected to fuel the expansion of the anti-osteoporosis and fracture healing market during the forecast period.
Principal Consultant
Complications During Disease Treatment to Restrain Market Growth
The market growth is likely to be hindered by the occurrence of complications during the disease treatment such as ulcers, irritable bowel syndrome, and nausea.
North America Driving growth at a Significant Pace
The North American anti-osteoporosis therapy and fracture healing market accounted for a revenue share of 33.5% in 2022. The United States alone accounted for a revenue share of 30.1% in the same year. The entire region is expected to grow with a CAGR of 4.5% during the forecast period.
The region is expected to remain at the forefront of the market due to the increased investment in research and development for the development of new drugs, a growing geriatric population, and a rising incidence of diseases resulting from changing lifestyles.
The increasing adherence to regulatory standards is further inducing growth in the regional market. With greater acceptance and commercialization of anti-osteoporosis therapy and fracture healing drugs in the United States, the demand for these treatments is expected to increase.
Most of the major players in the global anti-osteoporosis and fracture healing markets have their headquarters in the United States, creating opportunities for new markets in diagnosis and care. Also, the relatively higher cost of medications in countries like the United States enables a high-profit margin for the businesses to operate there.
Asia Pacific Driving Growth with a Significant CAGR
The Asia Pacific anti-osteoporosis therapy and fracture healing market is expected to grow with a significant CAGR of 4.3% from 2023 to 2033. The markets in China and India are projected to grow with a CAGR of 4.6% and 4.4% respectively during the forecast period.
The demand outlook in this region is expected to thrive at a significant rate in the forecast period, with India and China expected to remain most promising markets in the region. Some of the key factors driving the market growth in developing countries include increasing awareness about osteoporosis, a large pool of patients, a rising incidence of the geriatric population, changing lifestyles, and increasing healthcare expenditure.
China, being one of the most populous countries across the globe, is considered to have substantial growth potential in the anti-osteoporosis and fracture healing market. In addition, over the past decade, China has expanded its manufacturing capability, emerging as the leading supplier of drugs and raw materials in this market.
Malaysia is anticipated to be the second-largest market in South Asia for anti-osteoporosis treatment and fracture healing, following India. The market is projected to grow at a rate of over 3.1%. Malaysia is also an attractive destination for medical tourism due to its comparatively lower healthcare costs than the United States and the United Kingdom.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Bisphosphonates driving growth with a sizeable market share
Bisphosphonates segment accounted for a revenue share of 49.2% in 2022. This segment is expected to dominate the market while growing a CAGR of 6% during the forecast period. The increase in demand for targeted therapeutics and a shift in prescribing patterns towards bisphosphonates are contributing factors to segment growth.
Bisphosphonates are a type of medication that can slow down bone resorption, reducing the likelihood of spine and hip fractures. Although the process of bone regeneration is gradual, many patients may observe an improvement in bone density after five years of treatment with these drugs. Bisphosphonates are effective in treating various solid tumors affecting bones, such as multiple myeloma, by reducing skeletal morbidity.
These medications are increasingly being used in combination with anticancer therapies to prevent skeletal problems and alleviate bone pain. These factors are anticipated to keep the demand for bisphosphonate stable throughout the forecast period.
Oral Anti-Osteoporosis Therapy and Fracture Healing Drugs to be Most Preferred
Oral anti-osteoporosis therapy and fracture healing drugs accounted for a revenue share of 64.8% in 2022. The segment is expected to grow at a CAGR of 6.2% from 2023 to 2033.
Non-invasive therapeutics for anti-osteoporosis treatment and fracture healing are available in both oral and injectable forms. The oral drug segment is expected to capture over 65% of market share by end of 2023, as there is a rising demand for non-invasive therapies. Factors such as the increasing prevalence of needle phobia and needle stick injuries are expected to drive the demand for oral therapeutics.
The dominance of oral drugs in the market can be attributed to their convenience and wider availability in various regions. Compared to injectable treatment, oral drugs are more cost-effective and do not require the presence of nursing staff for administration. The increasing use of bisphosphonates for osteoporosis treatment is a significant driver of growth for the oral drug segment.
Start-ups have a significant role in recognizing potential growth prospects in any market. They are capable of generating high returns, which benefits the industry's expansion. Start-ups are generally more effective in converting inputs into outputs and are more flexible and adaptable to unstable market conditions. Below are some of the start-ups that are anticipated to drive growth in the anti-osteoporosis therapy and fracture healing market:
The anti-osteoporosis therapy and fracture healing market is extremely competitive and consists of various key industry players. These players are heavily investing in anti-osteoporosis therapy and fracture healing drugs market.
Key industry players are: Eli Lilly and Company, Pfizer, Inc, Amgen Inc., Merck, and Company Inc., Novartis International AG, F. Hoffmann La Roche Ltd., Teva Pharmaceuticals Industries Ltd., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson
Some recent developments in the market are:
Key industry players leverage organic growth strategies like acquisition, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global anti-osteoporosis therapy and fracture healing market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 14,051.6 million |
| Market Value in 2033 | US$ 22,427.6 million |
| Growth Rate | CAGR of 4.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization & Pricing | Available Upon Request |
North America is projected to emerge as a lucrative market.
The growth potential of the global market is 4.8% through 2033.
The rising complications during treatment is likely to limit market growth.
The United States is likely to secure a CAGR of 30.1% in 2023.
The market is estimated to secure a valuation of US$ 14,051.6 million in 2023.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Bisphosphonates 5.3.2. Calcitonin 5.3.3. Hormone Replacement Therapy 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Injectable 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Drug Stores 7.3.3. Retail Pharmacies 7.3.4. E-commerce 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Type 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Type 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Type 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Type 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Type 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Type 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Type 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Type 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Type 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Type 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Type 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Type 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Type 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Type 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Type 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Type 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Type 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Type 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Type 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Type 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Type 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Type 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Type 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Type 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Type 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Type 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Eli Lilly and Company 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Pfizer, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Amgen Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Merck and Company Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Novartis International AG 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. F. Hoffmann La Roche Ltd. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Teva Pharmaceuticals Industries Ltd. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. GlaxoSmithKline Plc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Sanofi S.A. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Johnson & Johnson 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Anti-Osteoporosis Therapy and Fracture Healing Market
